Abstract:Iodine-131‑labeled monoiodohypericin (131I‑Hyp) is a necrosis avid compound used as a complementary anticancer agent. Herein, the biodistribution in rats with re-perfused partial liver infarction (RPLI) was used to estimate its human internal radiation dosimetry. Iodine-123‑labeled monoiodohypericin (123I-Hyp) as a safer surrogate for 131I-Hyp was prepared with iodogen as oxidant. Determination of radiochemical yield and purification was performed by high performance liquid chromatography (HPLC). To control aggregation, the formulation was macroscopically and microscopically examined. Biodistribution of 123I-Hyp was studied in RPLI rats (n=18) at 4, 24 and 48 h post-injection. Tissue gamma counting (TGC), autoradiography and histology were performed. Dosimetry of 131I-Hyp in hepatic necrosis and in normal human organs was estimated using biodistribution data of 123I-Hyp, the Organ Level Internal Dose Assessment/Exponential Modeling (OLINDA/EXM®), a sphere model and male and female phantoms. A radiochemical yield of 95% was achieved in labeling of 123I-Hyp with a radiochemical purity of 99% after HPLC purification. In the Hyp added formulation, no macroscopic but minimal microscopic aggregation was observed. By TGC, selective accumulation in hepatic infarction and low uptake in viable liver of 123I‑Hyp/Hyp were detected, as confirmed by autoradiography and histology. Significantly higher doses of 131I-Hyp were delivered to necrotic (276‑93,600 mGy/MBq) than to viable (4.2 mGy/MBq) liver (P<0.05). In normal organs, 123I‑Hyp was eliminated within 24 h except for relatively high levels in the lungs and thyroid. Hepatobiliary elimination was a major pathway of 123I-Hyp causing high activity in the intestines. For both genders, dosimetry showed the longest residence time of 131I-Hyp in the remainder, followed by the lungs, intestines and thyroid. The highest absorbed radiation dose was seen in necrotic tissues and the shortest residence times and lowest absorbed radiation dose were found in the brain. 131I-Hyp selectively delivers higher radiation dose to necrosis compared with the rest of the body. Among normal organs, thyroids, lungs and intestines receive considerable radiation dose, which deserves cautious attention in developing this anticancer approach.

Preparation and validation of cyclodextrin-based excipients for radioiodinated hypericin applied in a targeted cancer radiotherapy

Radiosensitizer-based Injectable Hydrogel for Enhanced Radio-Chemotherapy of TNBC

Radioiodinated hypericin: its biodistribution, necrosis avidity and therapeutic efficacy are influenced by formulation

Biodistribution and radiation dosimetry of radioiodinated hypericin as a cancer therapeutic

Targetability and biodistribution of radioiodinated hypericin: comparison between microdosing and carrier-added preparations

Design, preparation and pharmacodynamics of ICG-Fe(III) based HCPT nanocrystals against cancer

Complex of 9-nitro-camptothecin in hydroxypropyl-β-cyclodextrin: In vitro and in vivo evaluation

Biodistribution and anti-tumor efficacy of intratumorally injected necrosis-avid theranostic agent radioiodinated hypericin in rodent tumor models

Particle Design and Inhalation Delivery of Iodine for Upper Respiratory Tract Infection Therapy

Biodistribution and tolerance of intravenous iodine-131-labelled hypericin in healthy dogs

A super-stable homogeneous Lipiodol-hydrophilic chemodrug formulation for treatment of hepatocellular carcinoma

Enhanced Nuclear Delivery and Cytotoxic Activity of Hydro-Xycamptothecin Using O/W Emulsions

Cyclodextrin-based iodophors with high iodine retention in solid state and in dilute solutions

Highly Effective Radioisotope Cancer Therapy with a Non-Therapeutic Isotope Delivered and Sensitized by Nanoscale Coordination Polymers

A Custom Radiopaque Thermoresponsive Chemotherapy-Loaded Hydrogel for Intratumoural Injection: An In Vitro and Ex Vivo Assessment of Imaging Characteristics and Material Properties

HP-β-CD for the formulation of IgG and Ig-based biotherapeutics

Microfluidic controllable preparation of iodine‐131‐labeled microspheres for radioembolization therapy of liver tumors

Host-guest inclusion systems of two bioactive natural products derivantives and three polyamine-modified β-cyclodextrins: Preparation, characterization, biological activity

Study of Glycol Chitosan-Carboxymethyl Β-Cyclodextrins As Anticancer Drugs Carrier.

A Cyclodextrin‐Hosted Ir(III) Complex for Ratiometric Mapping of Tumor Hypoxia In Vivo

Formulating 10-hydroxycamptothecin into nanoemulsion with functional excipient tributyrin: An innovative strategy for targeted hepatic cancer chemotherapy